Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors

被引：0
|
作者：
Philip J. Mease [1 ]
Shannon A. Ferrante [2 ]
Natalie J. Shiff [3 ]
Timothy P. Fitzgerald [3 ]
Soumya D. Chakravarty [4 ]
Jessica A. Walsh [3 ]
机构：
[1] Providence Swedish Medical Center,Rheumatology Research
[2] University of Washington School of Medicine,Adjunct, Community Health and Epidemiology
[3] Janssen Scientific Affairs,undefined
[4] LLC,undefined
[5] a Johnson & Johnson Company,undefined
[6] University of Saskatchewan,undefined
[7] Drexel University College of Medicine,undefined
[8] Salt Lake City Veterans Affairs Health,undefined
[9] University of Utah Health,undefined
来源：
Advances in Therapy | 2025年 / 42卷 / 2期
关键词：
Guselkumab; Psoriatic arthritis; Persistence; Real-world evidence; Subcutaneous interleukin-17A inhibitors;
D O I：
10.1007/s12325-024-03042-1
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：734 / 751
页数：17
相关论文
共 50 条
  • [41] PERSISTENCE OF MONOTHERAPY OR COMBINATION THERAPY WITH DISEASE-MODIFYING AGENTS IN PATIENTS WITH PSORIATIC ARTHRITIS IN A REAL-WORLD SETTING
    Mease, P. J.
    Accortt, N. A.
    Rebello, S.
    Etzel, C.
    Harrison, R. W.
    Aras, G. A.
    Gharaibeh, M. M. F.
    Greenberg, J. D.
    Collier, D. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 612 - 612
  • [42] PERSISTENCE OF MONOTHERAPY OR COMBINATION THERAPY WITH DISEASE-MODIFYING AGENTS IN PATIENTS WITH PSORIATIC ARTHRITIS IN A REAL-WORLD SETTING
    Saidane, O.
    Sellami, M.
    Barhoumi, R.
    Ben Tekaya, A.
    Ajlani, H.
    Tekaya, R.
    Mahmoud, I.
    Abdelmoula, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 612 - 612
  • [43] Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
    Mease, Philip J.
    Ogdie, Alexis R.
    Tesser, John
    Shiff, Natalie
    Lin, Iris
    Chakravarty, Soumya
    Kelleman, Mike
    Dodge, Rhiannon
    McLean, Robert
    Broadwell, Aaron
    Kavanaugh, Arthur
    Merola, Joseph F.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2767 - 2770
  • [44] PERSISTENCE OF SEQUENCING GUSELKUMAB OR TNFI AS A SECOND-LINE THERAPY FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN REAL WORLD PRACTICE IN SPAIN - MANHATTAN STUDY
    Mendez Diaz, L.
    Gonzalez Molina, R.
    Marin Huertas, C.
    Joven-Ibanez, B.
    Fernandez-Nebro, A.
    Garcia Casares, E.
    Mateo Soria, L.
    Hernandez del Rio, A.
    Blanco-Morales, E. A.
    Malave Calzada, J.
    Salles Lizarzaburu, M.
    Ros Vilamajo, I
    Cervantes Perez, E. C.
    Hernandez-Hernandez, V
    Castro Oreiro, S.
    Urruticoechea Arana, A.
    Orpinell Palacio, L.
    Campos Esteban, J. A.
    Veroz Gonzalez, R.
    Camacho Alcazar, O.
    Moreno-Gil, M. P.
    Aragon Diez, A.
    Moreno Ramos, M. J.
    Maceiras-Pan, F. J.
    Diaz-Castroverde, S.
    Ramirez Garcia, J.
    Munoz-Fernandez, S.
    Pinto Tasende, J. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (09) : 89 - 90
  • [45] On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study
    Sermsaksasithorn, Pim
    Wongtada, Chanidapa
    Chaaim, Varin
    Chongpison, Yuda
    Asawanonda, Pravit
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (07) : 2963 - 2974
  • [46] Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study
    Beatriz Joven
    Raquel Hernández Sánchez
    Eva Pérez-Pampín
    Ángel Aragón Díez
    Raquel Almodóvar
    Ángels Martínez-Ferrer
    Joaquín Belzunegui
    Esteban Rubio
    Silvia Díaz-Cerezo
    Sebastián Moyano
    Manuel Gómez-Barrera
    María Yébenes
    Mercedes Núñez
    Rheumatology and Therapy, 2023, 10 : 1319 - 1333
  • [47] Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study
    Philipp Sewerin
    Kathrin Borchert
    Dominic Meise
    Matthias Schneider
    Jörg Mahlich
    Rheumatology and Therapy, 2021, 8 : 483 - 497
  • [48] PERSISTENCE AND HEALTHCARE RESOURCE USE (HCRU) IN PATIENTS INITIATING ETANERCEPT TREATMENT FOR ANKYLOSING SPONDYLITIS (AS) OR PSORIATIC ARTHRITIS (PSA) IN GERMANY: A REAL-WORLD ANALYSIS
    Baraliakos, X.
    Poddubnyy, D.
    Behrens, F.
    Curiale, C.
    Tarallo, M.
    Daly, Hernandez A. C.
    Behmer, O.
    Hudson, N.
    Gray, C.
    Cappelleri, J. C.
    VALUE IN HEALTH, 2019, 22 : S432 - S432
  • [49] Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study
    Joven, Beatriz
    Sanchez, Raquel Hernandez
    Perez-Pampin, Eva
    Diez, Angel Aragon
    Almodovar, Raquel
    Martinez-Ferrer, Angels
    Belzunegui, Joaquin
    Rubio, Esteban
    Diaz-Cerezo, Silvia
    Moyano, Sebastian
    Gomez-Barrera, Manuel
    Yebenes, Maria
    Nunez, Mercedes
    RHEUMATOLOGY AND THERAPY, 2023, 10 (05) : 1319 - 1333
  • [50] Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study
    Rieke Alten
    P. G. Conaghan
    V. Strand
    E. Sullivan
    S. Blackburn
    H. Tian
    K. Gandhi
    S. M. Jugl
    A. Deodhar
    Clinical Rheumatology, 2019, 38 : 1615 - 1626
12345